How many years can you live on bosutinib/bosutinib?

Bosutinib/Bosutinib is a targeted drug specifically designed to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). Its efficacy and patient survival are affected by many factors, such as the patient's age, stage of the disease, individual physical condition, and response to treatment. Therefore, how many years you can live is not a question that can be answered simply, but requires comprehensive consideration of multiple aspects.

Clinical trial results of bosutinib show that the drug has shown good therapeutic effects in many patients. According to relevant studies, bosutinib can effectively control disease progression in the early stage of treatment and achieve a high complete response rate and progression-free survival. This means that many patients can maintain a long-term stable state or even achieve complete remission after receiving bosutinib treatment, thus extending their survival.

Secondly, individual differences among patients can also significantly affect survival time. For example, younger patients generally have stronger physical fitness and better tolerance, and are often better able to withstand the side effects of treatment and achieve better results during treatment. Older patients or those with other serious diseases may face more challenges during treatment, thus affecting overall survival.

Furthermore, patient resistance to bosutinib is also an important factor. As treatment continues, some patients may develop resistance to bosutinib. At this time, doctors may need to adjust the treatment plan, including switching to other types of targeted drugs or chemotherapy drugs. Timely adjustment of treatment and response strategies to drug resistance will also directly affect the survival of patients.

In addition, regular follow-up and monitoring are also important aspects to ensure patient survival. During the treatment process, doctors will regularly evaluate the patient's blood picture and other related indicators to judge the treatment effect and detect potential problems in a timely manner. Through early intervention, the survival rate of patients can be effectively improved.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC6068045/